Company: KROS
Filing Date: 2025-09-08
Form Type: 8-K
Source: 0001664710-25-000081
Chunk: 0

Company: Keros Therapeutics, Inc.
Filing Date: 2025-09-08
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item 8.01 Other Events.

On September 8, 2025, Keros Therapeutics, Inc. (the “ Company”) issued a press release announcing that it presented additional clinical data from its Phase 1 clinical trial of KER-065 in healthy male volunteers at the American Society of Bone and Mineral Research 2025 Annual Meeting on Saturday, September 6, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and, other than the quotes contained therein, is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.